Search results | NICE

1 result

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Cancer service guidelines Remove Cancer service guidelines filter

Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation

We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.

Type

Technology appraisal guidance

Status

In consultation